New monoclonal antibodies to oestrogen and progesterone receptors effective for paraffin section immunohistochemistry.
Assessment of oestrogen and progesterone receptors (ER and PgR) in breast cancer is widely used for the prediction of response to endocrine therapy and as a prognostic marker. Cytosolic assays have been replaced in many centres by immunochemical techniques, which have many advantages including applicability to small samples, simplicity, and cost-effectiveness. This study describes the generation and characterisation of two novel murine monoclonal antibodies recognizing ER and PgR, designated NCL-ER-6F11 and NCL-PGR respectively, which are effective in heat-treated formalin-fixed, paraffin-embedded tissue. The antibodies have been characterized by Western blotting and by immunohistochemistry on normal and pathological breast and other tissues. NCL-ER-6F11 has been shown to compare favourably with a currently available ER antibody. These antibodies may prove of value in the assessment of hormone receptor status in human breast cancer.
Bevitt
D J
DJ
Novocastra Laboratories Ltd., Newcastle upon Tyne, U.K.
Milton
I D
ID
Piggot
N
N
Henry
L
L
Carter
M J
MJ
Toms
G L
GL
Lennard
T W
TW
Westley
B
B
Angus
B
B
Horne
C H
CH
D000911:Antibodies, Monoclonal / Q000096:biosynthesis*; D014408:Biomarkers, Tumor / Q000276:immunology* / Q000378:metabolism; D015153:Blotting, Western; D001943:Breast Neoplasms / Q000378:metabolism*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D016612:Paraffin Embedding; D011960:Receptors, Estrogen / Q000276:immunology* / Q000378:metabolism; D011980:Receptors, Progesterone / Q000276:immunology* / Q000378:metabolism; D014407:Tumor Cells, Cultured
D000911:Antibodies, Monoclonal; D014408:Biomarkers, Tumor; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone